MeiraGTx 的股票在与 Hologen 达成 $200M 的交易以开发帕金森病治疗方法后飙升。 MeiraGTx's stock surged after a $200M deal with Hologen to develop a Parkinson's treatment.

MeiraGTx的库存在与Hologen合作开发帕金森氏病治疗后上升了17%。 MeiraGTx's stock rose 17% after a collaboration with Hologen to develop a Parkinson's disease treatment. 这笔交易包括一笔2亿美元的预付付款和一个合资企业Hologen Neuro AI有限公司,为AAV-GAD开发工作提供了2.3亿美元的资金。 The deal includes a $200 million upfront payment and a joint venture, Hologen Neuro AI Ltd, with $230 million funding for AAV-GAD development. 该伙伴关系旨在推广神经退化障碍遗传药物。 The partnership aims to advance genetic medicines for neurodegenerative disorders. MeiraGTx公司还报告了AAV-GAD公司的积极临床数据,并获得林业发展局指定用于其他疗法。 MeiraGTx also reported positive clinical data for AAV-GAD and received FDA designations for other therapies.